round cell sarcoma with EWSR1-non-ETS fusion
diseaseOn this page
Summary
round cell sarcoma with EWSR1-non-ETS fusion (MONDO:0958160) is a cancer and 3 clinical trials. Top therapeutic interventions include fludeoxyglucose f 18, ifosfamide, and regorafenib. A subtype of small cell sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | round cell sarcoma with EWSR1-non-ETS fusion |
| Mondo ID | MONDO:0958160 |
| DOID | DOID:0081406 |
| NCIT | C178459 |
| UMLS | C4727985 |
| MedGen | 1790023 |
| Is cancer (heuristic) | yes |
Disease family
This is a subtype of small cell sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › small cell sarcoma › round cell sarcoma with EWSR1-non-ETS fusion
Related subtypes (5): small cell osteogenic sarcoma, mesenchymal chondrosarcoma, desmoplastic small round cell tumor, EWSR1-negative small round cell tumor, sarcoma with BCOR genetic alterations
Subtypes (4): childhood round cell sarcoma with EWSR1-non-ETS fusion, round cell sarcoma with EWSR1-NFATC2 gene fusion, round cell sarcoma with EWSR1-PATZ1 gene fusion, round cell sarcoma with FUS-NFATC2 gene fusion
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06820957 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body |
| NCT06526897 | Not specified | NOT_YET_RECRUITING | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma |
| NCT07188532 | Not specified | RECRUITING | Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| REGORAFENIB | 4 | 1 |
| CHEMBL541887 | 0 | 1 |